Your Article Summary
See Latest ArticlesImproved Survival with Single-Agent Paclitaxel Consolidation/Maintenance Therapy in Advanced Ovarian Carcinoma
Oncology (Karger), 03/26/07
John P. Micha, et al. - Conclusion: We recognize the important limitations of this study, particularly its sample size and nonrandomized nature. However, these data provide support for the conclusion that paclitaxel 'maintenance/consolidation' therapy may favorably impact overall and progression-free survival in advanced ovarian cancer patients who achieve an excellent response to primary platinum-based chemotherapy
Related Articles
Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas
BMC Cancer, 10/21/09
Relevance Score: 69%
Serous papillary peritoneal carcinoma: Unknown primary tumour, ovarian cancer counterpart or a distinct entity? A systematic review
Critical Reviews in Oncology/Hematology, 11/12/09
Relevance Score: 67%
Precursors of endometrial and ovarian carcinoma
Virchows Archiv, 11/02/09
Relevance Score: 67%
Combination of MUC5ac and WT-1 immunohistochemistry is useful in distinguishing pancreatic ductal carcinoma from ovarian serous carcinoma in effusion cytology
Diagnostic Cytopathology, 10/28/09
Relevance Score: 67%
XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma
European Journal of Obstetrics & Gynecology and Reproductive Biology, 10/09/09
Relevance Score: 67%
Today in Gynecologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Emerging role of pemetrexed in ovarian cancer
Expert Review of Anticancer Therapy, 12/04/09
Target genes suitable for silencing approaches and protein product interference in ovarian epithelial cancer
Cancer Treatment Reviews, 12/04/09
Vaginal Schwannoma in a case with uterine myoma
Annals of Diagnostic Pathology, 12/04/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Management of patients with advanced bladder cancer following major response to systemic chemotherapy
Expert Review of Anticancer Therapy, 12/04/09
ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer
Expert Review of Anticancer Therapy, 12/04/09
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/04/09